Efficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer: impact of chemotherapy regimen and sequence on pathologic complete response
Wirksamkeitsvergleich von Toripalimab versus Pembrolizumab in der neoadjuvanten Behandlung von Brustkrebs: Einfluss von Chemotherapie-Regime und Sequenz auf die pathologische Komplettremission
Frontiers in Oncology · 19.12.2025 · 15
DOI: 10.3389/fonc.2025.1699963 ↗Auf einen Blick
In einer retrospektiven Studie mit 114 Brustkrebspatient:innen war Toripalimab hinsichtlich pCR ähnlich wirksam wie Pembrolizumab. Die Chemotherapie-Sequenz beeinflusste die pCR deutlich.
Fragestellung
Wie wirksam und sicher ist Toripalimab im Vergleich zu Pembrolizumab in der neoadjuvanten Behandlung von Brustkrebs, und welchen Einfluss haben Zykluszahl, Platin und Sequenz auf pCR?
Methode
Retrospektive Real-World-Studie mit 114 Patient:innen; Vergleich von Toripalimab und Pembrolizumab sowie Subgruppen nach Immuntherapiezyklen, Platin und Chemotherapie-Sequenz.
Ergebnisse
Keine signifikanten Unterschiede zwischen Toripalimab und Pembrolizumab bei tpCR (56,8 % vs. 50,0 %; P=0,777) oder RCB-0 (56,8 % vs. 48,6 %; P=0,903). TCb-EC erreichte die höchste tpCR-Rate (79,2 %).
Schlussfolgerung der Autor:innen
Toripalimab zeigte eine nicht unterlegene Wirksamkeit gegenüber Pembrolizumab. Die Chemotherapie-Sequenz, besonders TCb-EC, sagte die pCR voraus; Zykluszahl und Platin beeinflussten die pathologischen Ergebnisse nicht.
Kernaussagen
- Toripalimab und Pembrolizumab unterschieden sich nicht signifikant in tpCR oder RCB-0.
- TCb-EC erzielte die höchste tpCR-Rate mit 79,2 %.
- Zykluszahl und Platin-basierte Chemotherapie zeigten keinen Einfluss auf die pathologischen Ergebnisse.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.12.2025. Verfasst von Yunjiao Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This real-world study aimed to compare the efficacy and safety of the domestically developed PD-1 inhibitor toripalimab with pembrolizumab in the neoadjuvant treatment of breast cancer, and to further investigate the impact of treatment cycles, platinum-based chemotherapy, and chemotherapy sequencing on pathologic complete response (pCR).
Methods
This retrospective study included 114 breast cancer patients who received neoadjuvant therapy with either toripalimab or pembrolizumab at the First Affiliated Hospital of Air Force Medical University between January 2021 and January 2025. Participants were stratified into groups based on: (1) immunotherapy cycles (completed 8 cycles vs. incomplete); (2) chemotherapy regimen (platinum vs. non-platinum); (3) chemotherapy sequence (EC-T, EC-TCb, T-EC, TCb-EC, or other); and (4) PD-1 inhibitor type (toripalimab vs. pembrolizumab). The primary endpoint was total pCR (tpCR; ypT0/is ypN0). Secondary endpoints included breast pCR (bpCR) and residual cancer burden (RCB). Statistical analyses incorporated Chi-square tests and Fisher’s exact tests for group comparisons. Baseline characteristics were compared across groups to assess the potential for confounding.
Results
No significant differences were observed in tpCR (56.7% vs. 46.8%; P=0.297) or RCB-0 rates (56.7% vs. 44.7%; P=0.524) between patients completing versus not completing 8 immunotherapy cycles. The tpCR rate did not differ significantly between platinum-based and non-platinum-based regimens (53.6% vs. 51.7%, P=0.843). Chemotherapy sequence significantly affected efficacy: the TCb-EC group achieved the highest tpCR rate (79.2%), significantly outperforming EC-T (56.4%) and other regimens (27.3%). Toripalimab and pembrolizumab showed no significant difference in tpCR rate (56.8% vs. 50.0%, P=0.777) or RCB-0 rate (56.8% vs. 48.6%, P=0.903).
Conclusion
Toripalimab demonstrated non-inferior efficacy compared to pembrolizumab in the neoadjuvant treatment of breast cancer. Chemotherapy sequence—particularly the TCb-EC regimen—significantly predicted pCR, while immunotherapy cycle number and platinum use did not influence pathologic outcomes. These real-world findings support toripalimab’s clinical use and underscore the importance of optimizing chemoimmunotherapy sequencing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
- Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Zitieren
APA
Zhang, Y., Zhang, B., Chen, X., Zhang, X., Liu, C., Wang, Z., & Ling, R. (2025). Efficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer: impact of chemotherapy regimen and sequence on pathologic complete response. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1699963
Vancouver
Zhang Y, Zhang B, Chen X, Zhang X, Liu C, Wang Z, et al. Efficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer: impact of chemotherapy regimen and sequence on pathologic complete response. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1699963
BibTeX
@article{Zhang2025,
author = {Zhang, Yunjiao and Zhang, Bo and Chen, Xi and Zhang, Xue and Liu, Chutuo and Wang, Zhe and Ling, Rui},
title = {Efficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer: impact of chemotherapy regimen and sequence on pathologic complete response},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1699963}
}
EUVIMED